In 2021, Israeli startup Redefine Meat plans to launch a 3D printer that will allow customers to produce plant-based flank steak at home. Engadget reports: Redefine Meat says that through 3D printing, it's able to create plant-based meat with the same "appearance, texture and flavor of animal meat," according to its website. Texture specifically seems to be the 3D printer's hallmark achievement. "You need a 3D printer to mimic the structure of the muscle of the animal," Redefine Meat CEO Eshchar Ben-Shitrit told Reuters.

3D printing differs from other methods companies have used for reproducing meat taste and texture. Both Impossible Foods and Beyond Meat use combinations of plant-based proteins, oils and binders, like methylcellulose and potato starch, to achieve a realistic texture for their ground beef and patties -- though the texture of ground beef is arguably easier to achieve than that of steak. Atlast Food uses mushroom fibers to emulate animal tissue in its meatless bacon.

An anonymous reader quotes The Washington Post: In the global race for a coronavirus vaccine, more than 100 labs, universities and drug companies have started off on experimental missions. But just 11 candidate vaccines, according to the World Health Organization, have reached the stage of clinical testing. The WHO says that only Oxford University's vaccine has reached what is known as Phase 3, the final and largest-scale trial... "There is quite a strong probability that the vaccine will work," said Walter Ricciardi, the World Health Organization's Italian government adviser.

But the vaccine is far from a sure thing, according to experts. It might not work, or it might give immunity to only some of those who are injected. Even once a vaccine makes it to market, it remains unknown whether it will offer long-term protection, or only for a year or two. The world will ultimately need more than one vaccine anyway, as demand will soar beyond what any one company could produce. "The expectation is that we will have a protective vaccine. Probably more than one," said Antonio Cassone, the former head of the infectious-disease department at Italy's national health institute.

"But nobody will know at that time how long the protection will last. We don't know the antibody duration. This will be yet another jump into the unknown."

A Chinese biotech firm has reported encouraging results in early-stage clinical trials and is also among the front-runners to crack the vaccine code.
The article adds that Oxford's vaccine "proved effective and safe with rhesus monkeys during the earliest stage of experimentation."

Iceland is the most sparsely-populated country in Europe, with a population of 364,134 spread across 40,000 square miles (103,000 square kilometers). But the New Yorker notes Iceland has "virtually eliminated" Covid-19 cases -- and tries to explore how they did it.

By February 28th, Iceland had already implemented a contact-tracing team. "And then, two hours later, we got the call," remembers a detective with the Reykjavík police department. A man who'd recently been skiing in the Dolomites had become the country's first known coronavirus patient... Anyone who'd spent more than fifteen minutes near the man in the days before he'd experienced his first symptoms was considered potentially infected. ("Near" was defined as within a radius of two metres, or just over six feet.) The team came up with a list of fifty-six names. By midnight, all fifty-six contacts had been located and ordered to quarantine themselves for fourteen days.

The first case was followed by three more cases, then by six, and then by an onslaught. By mid-March, confirmed COVID cases in Iceland were increasing at a rate of sixty, seventy, even a hundred a day. As a proportion of the country's population, this was far faster than the rate at which cases in the United States were growing. The number of people the tracing team was tracking down, meanwhile, was rising even more quickly. An infected person might have been near five other people, or fifty-six, or more. One young woman was so active before she tested positive — going to classes, rehearsing a play, attending choir practice — that her contacts numbered close to two hundred. All were sent into quarantine.

The tracing team, too, kept growing, until it had fifty-two members. They worked in shifts out of conference rooms in a Reykjavík hotel that had closed for lack of tourists. To find people who had been exposed, team members scanned airplane manifests and security-camera footage. They tried to pinpoint who was sitting next to whom on buses and in lecture halls. One man who fell ill had recently attended a concert. The only person he remembered having had contact with while there was his wife. But the tracing team did some sleuthing and found that after the concert there had been a reception. "In this gathering, people were hugging, and eating from the same trays," Pálmason told me. "So the decision was made — all of them go into quarantine." If you were returning to Iceland from overseas, you also got a call: put yourself in quarantine. At the same time, the country was aggressively testing for the virus — on a per-capita basis, at the highest rate in the world...

[B]y mid-May, when I went to talk to Pálmason, the tracing team had almost no one left to track. During the previous week, in all of Iceland, only two new coronavirus cases had been confirmed. The country hadn't just managed to flatten the curve; it had, it seemed, virtually eliminated it.
A biotech firm called deCODE Genetics (owned by the American multinational biopharmaceutical company Amgen) also offered its own facilities for screening tests, which "picked up many cases that otherwise would have been missed," according to the article. "These cases, too, were referred to the tracing team. By May 17th, Iceland had tested 15.5 per cent of its population for the virus." Meanwhile, deCODE was also sequencing the virus from every Icelander whose test had come back positive. As the virus is passed from person to person, it picks up random mutations. By analyzing these, geneticists can map the disease's spread...

[R]esearchers at deCODE found that, while attention had been focussed on Italy, the virus had been quietly slipping into the country from several other nations, including Britain. Travellers from the West Coast of the U.S. had brought in one strain, and travellers from the East Coast another. The East Coast strain had been imported to America from Italy or Austria, then exported back to Europe.

pacopico writes: A startup called Variant Bio has quietly been going around the world for the past couple of years, looking for genetic outliers. We're talking about people with super high metabolisms, amazing eyesight, the ability to hold their breaths for really long times. Variant wants to sequence their DNA and come up with a new class of drugs based off these traits found among isolated, indigenous people. The whole business is sort of the opposite of 23andMe or Ancestry where you sequence a ton of people and hope something interesting pops out. Instead, you're going to the obviously interesting spots and then trying to strike deals to get the DNA and turn the interesting genes into the basis of drugs. Tons of ethical and moral questions but very sci-fi and at the frontier of bio-tech.

America's Environmental Protection Agency "granted permission for genetically engineered mosquitoes to be released into the Florida Keys and around Houston to see if they can help limit the spread of mosquito-borne illnesses," writes Bloomberg Environment.

clovis (Slashdot reader #4,684) shared their report on ab experimental use permit granted to British biotech company Oxitec Ltd: Oxitec's first field trial in Brazil achieved up to a 96% suppression of target disease transmitting mosquito populations in dense urban settings, the company said. But in public comments on the permit approval docket, Jaydee Hanson, policy director at the Washington, D.C.-based Center for Food Safety, questioned Oxitec's claims and warned of other possible dangers.

"Most (but not all) of the GE mosquitoes' offspring die at the late larval stage, in the water where the female mosquitoes lay their eggs," Hanson wrote."This partial survival rate, even if low (a reported 3 to 4% in laboratory conditions), would lead to the establishment of hybrid mosquitoes in the environment, which might possess altered properties, including the potential for enhanced disease transmission or resistance to insecticides," Hanson said.
The U.S. agency said it "looks forward to receiving field test results regarding the effectiveness of this promising new tool that could help combat the spread of mosquito-borne diseases like the Zika virus."

"The race for a vaccine to combat the new coronavirus is moving faster than researchers and drugmakers expected," reported Dow Jones News Services this week, "with Pfizer Inc. joining several other groups saying that they had accelerated the timetable for testing and that a vaccine could be ready for emergency use in the fall." Pfizer said Tuesday it will begin testing of its experimental vaccine in the U.S. as early as next week. On Monday, Oxford University researchers said their vaccine candidate could be available for emergency use as early as September if it passes muster in studies, while biotech Moderna Inc. said it was preparing to enter its vaccine into the second phase of human testing... If the vaccine shows signs of working safely in the study, Moderna said the third and final phase of testing could start in the fall. The company said it could seek FDA approval to sell the vaccine by year's end, if it succeeds in testing...

Merck & Co., a longtime maker of vaccines, said it is talking to potential partners about three different technologies to manufacture coronavirus vaccines... Johnson & Johnson said earlier this month it shaved months off the usual timelines for developing a vaccine, and expects to start human testing of a coronavirus candidate as soon as September, with possible availability on an emergency-use basis in early 2021.
SFGate also reports that GlaxoSmithKline and the French pharmaceutical company Sanofi "expect their vaccine will be ready for human testing in the second half of 2020."

And the Associated Press notes that America's Food and Drug Administration (FDA) "is tracking at least 86 active different approaches among pharmaceutical companies, academic researchers and scientists around the globe." Dr. Peter Marks, director of the agency's Center for Biologics Evaluation and Research, adds "We expect about two dozen more to enter clinical trials by this summer and early fall."

Long-time Slashdot reader Charlotte Web writes: "Virus researchers say there is virtually no chance that the new coronavirus was released as result of a laboratory accident in China or anywhere else," writes NPR, citing "10 leading scientists who collect samples of viruses from animals in the wild, study virus genomes and understand how lab accidents can happen."
NPR reports: "All of the evidence points to this not being a laboratory accident," says Jonna Mazet, a professor of epidemiology at the University of California, Davis and director of a global project to watch for emerging viruses called PREDICT. Rather, the experts interviewed by NPR all believe that the virus was transmitted between animals and humans in nature, as has happened in previous outbreaks — from Ebola to the Marburg virus — and with other known coronaviruses such as SARS and MERS...

Lowering the odds further still, when researchers begin to work in the lab to see what they've collected, the samples they handle aren't actually infectious. Mazet says they are "inactivated," a chemical process that breaks apart the virus itself while preserving its genetic material for study... These protocols are used by scientists all over the world, including in China. Mazet says that the staff at the Wuhan Institute of Virology, where much of the suspicion has been focused, has been trained by U.S. scientists as part of the PREDICT program. Scientists working there follow the rules, Mazet says.

Mazet says researchers at the Wuhan institute were so good, they actually helped to shape the protocols. "They were not only completing all of those trainings, but they were also weighing in and helping us to make those trainings very strong from a safety perspective," she says.
U.S. intelligence officials have now also joined additional scientists saying there's zero evidence that the virus escaped from a lab. And NPR also interviewed Peter Daszak, the president of the EcoHealth Alliance researching the origins of pandemics, who points out that nearly 3% of the population in China's rural farming regions near wild animals already had antibodies to coronaviruses similar to SARS. "We're finding 1 to 7 million people exposed to these viruses every year in Southeast Asia; that's the pathway. It's just so obvious to all of us working in the field..."

"We have a bat virus in my neighborhood in New York killing people. Let's get real about this."

America and India "have run an internationally recognized joint vaccine development program for more than three decades," writes long-time Slashdot reader retroworks. And today the BBC reported the two countries are now working together on vaccines against the new coronavirus: India is among the largest manufacturer of generic drugs and vaccines in the world. It is home to half a dozen major vaccine makers and a host of smaller ones, making doses against polio, meningitis, pneumonia, rotavirus, BCG, measles, mumps and rubella, among other diseases. Now half a dozen Indian firms are developing vaccines against the virus that causes Covid-19.

One of them is Serum Institute of India, the world's largest vaccine maker by number of doses produced and sold globally... Now the firm has stitched up collaboration with Codagenix, an American biotech company, to develop a "live attenuated" vaccine, among the more than 80 reportedly in development all over the world... "We are planning a set of animal trials [on mice and primates] of this vaccine in April. By September, we should be able to begin human trials," Adar Poonawalla, chief executive officer of Serum Institute of India, told me over the phone. Mr Poonawalla's firm has also partnered to mass produce a vaccine being developed by the University of Oxford and backed by the UK government...

"It's pretty clear the world is going to need hundreds of millions of doses, ideally by the end of this year, to end this pandemic, to lead us out of lockdown," Prof Adrian Hill, who runs the Jenner Institute at Oxford, told the BBC's Health and Science correspondent James Gallagher. This is where Indian vaccine makers have a head start over others. Mr Poonawalla's firm alone has an extra capacity of 400 to 500 million doses. "We have lots of capacity as we have invested in it," he says.

There's more. Hyderabad-based Bharat Biotech had announced a partnership with the University of Wisconsin Madison and US-based firm FluGen to make almost 300 million doses of a vaccine for global distribution. Zydus Cadilla is working on two vaccines, while Biological E, Indian Immunologicals, and Mynvax are developing a vaccine each. Another four or five home-grown vaccines are in early stages of development.
In the article the World Health Organization's chief scientist also applauds "the entrepreneurs and pharmaceutical companies who invested in quality manufacturing and in processes that made it possible to produce in bulk.

"The owners of these companies have also had the goal of doing good for the world, while also running a successful business and this model is a win-win for all."

"Germany changed course on Sunday over which type of smartphone technology it wanted to use to trace coronavirus infections," reports Reuters, "backing an approach supported by Apple and Google along with a growing number of other European countries." Chancellery Minister Helge Braun and Health Minister Jens Spahn said in a joint statement that Berlin would adopt a "decentralised" approach to digital contact tracing, thus abandoning a home-grown alternative that would have given health authorities central control over tracing data.

In Europe, most countries have chosen short-range Bluetooth "handshakes" between mobile devices as the best way of registering a potential contact, even though it does not provide location data. But they have disagreed about whether to log such contacts on individual devices or on a central server -- which would be more directly useful to existing contact tracing teams that work phones and knock on doors to warn those who may be at risk. Under the decentralised approach, users could opt to share their phone number or details of their symptoms -- making it easier for health authorities to get in touch and give advice on the best course of action in the event they are found to be at risk. This consent would be given in the app, however, and not be part of the system's central architecture...

Germany as recently as Friday backed a centralised standard called Pan-European Privacy-Preserving Proximity Tracing (PEPP-PT), which would have needed Apple in particular to change the settings on its iPhones.

When Apple refused to budge there was no alternative but to change course, said a senior government source.
The article notes Germany had also received opposition in a recently-published letter signed by hundreds of scientists.

It had warned that Germany's original plan for centralized tracing would allow "unprecedented surveillance of society at large".

"Australia's coronavirus tracing app, dubbed COVIDSafe, has been released as the nation seeks to contain the spread of the deadly pandemic," reports ABC.net.au: People who download the app will be asked to supply a name, which can be a pseudonym, their age range, a mobile number and post code. Those who download the software will be notified if they have contact with another user who tests positive for coronavirus... Using Bluetooth technology, the app "pings" or exchanges a "digital handshake" with another user when they come within 1.5 metres of each other, and then logs this contact and encrypts it.

The data remains encrypted on a user's phone for 21 days, after which it is deleted if they have not been in contact with a confirmed case. The application will have two stages of consent that people will have to agree to: initially when they download the app so data can be collected, and secondly to release that data on their phone if they are diagnosed with the virus. If a person with the app tested positive to COVID-19, and provided they consent to sharing the information, it will be sent to a central server. From here, state and territory health authorities can access it and start contacting other people who might have contracted coronavirus...

The app is voluntary and it will be illegal to force anyone to download it.
In addition, Australia "will make it illegal for non-health officials to access data collected on smartphone software to trace the spread of the coronavirus," reports Reuters, citing comments Friday by Prime Minister Scott Morrison "amid privacy concerns raised by the measure." Australia has so far avoided the high death toll of other countries, with only 78 deaths, largely as a result of tough restrictions on movement that have brought public life to a standstill. The federal government has said existing "social distancing" measures will remain until at least mid-May, and that its willingness to relax them will depend on whether people download the smartphone "app" to identify who a person with the illness has had contact with...

Morrison also confirmed a local media report which said the data would be stored on servers managed by AWS, a unit of U.S. internet giant Amazon.com Inc, but added that "it's a nationally encrypted data store".
"The spec for it is very privacy-positive," writes Slashdot reader Bleve97, adding "It will be interesting to see what it looks like once it's been disassembled in a sandbox and played with!"

And Slashdot reader betsuin has already installed it (adding that the app "does not require GPS... I've installed, GPS is off on my rooted device."

"Two research groups say they've independently built quantum devices that can operate at temperatures above 1 Kelvin — 15 times hotter than rival technologies can withstand," reports IEEE Spectrum. (In an article shared by Slashdot reader Wave723.)

"The ability to work at higher temperatures is key to scaling up to the many qubits thought to be required for future commercial-grade quantum computers..." HongWen Jiang, a physicist at UCLA and a peer reviewer for both papers, described the research as "a technological breakthrough for semiconductor based quantum computing." In today's quantum computers, qubits must be kept inside large dilution refrigerators at temperatures hovering just above absolute zero. Electronics required to manipulate and read the qubits produce too much heat and so remain outside of the fridge, which adds complexity (and many wires) to the system...

"To me, these works do represent, in rapid succession, pretty big milestones in silicon spin qubits," says John Gamble, a peer reviewer for one of the papers and a senior quantum engineer at Microsoft. "It's compelling work...." Moving forward, Gamble is interested to see if the research groups can scale their approach to include more qubits. He's encouraged by their efforts so far, saying, "The fact that we're seeing these types of advances means the field is progressing really well and that people are thinking of the right problems."
Besides Microsoft, Google and IBM have also "invested heavily in superconducting qubits," the article points out. And there's also a hopeful comment from Lee Bassett, a physicist focused on quantum systems at the University of Pennsylvania. "Each time these silicon devices pass a milestone — and this is an important milestone — it's closer and closer to the inflection point.

"This infrastructure of integrated, silicon-based electronics could take over, and this technology could just explode."

Newsweek reports: There is no evidence to back claims the coronavirus that has caused the COVID-19 pandemic emerged from a lab in China, scientists have told Newsweek.

Adam Lauring, an associate professor at the University of Michigan Medical School and an expert in the evolution of viruses, told Newsweek: "This claim is a conspiracy theory and it is not supported at all by the available data... The SARS-CoV-2 virus has some key differences in specific genes relative to previously identified coronaviruses — the ones a laboratory would be working with," said Lauring. "This constellation of changes makes it unlikely that it is the result of a laboratory 'escape.'"

Alexandre Hassanin, a lecturer at France's Sorbonne University National Museum of Natural History department of origins and evolution, similarly highlighted to Newsweek: "Even if it is difficult to prove that a laboratory accident did not take place, you should know that SARS-CoV-2 is not closely related to any previous viruses; it was never sequenced (even partially) in previous studies, and the COVID-19 outbreak began in November/December, as in previous SARS epidemic events (2002 and 2003)."

Hassanin said: "These two points suggest therefore that the current outbreak was not the consequence of a laboratory accident."
An anonymous reader adds: Today the Associated Press also called it "an outlier theory" being spread by president Trump and officials in his administration "without the weight of evidence."

On Twitter, Eric Hundman, an Assistant Professor at NYU Shanghai, had stern words for anyone still spreading this misinformation. "Insinuating that the virus escaped from a lab in China by saying 'well, there's no evidence that it didn't' is not only untrue, it amounts to disinformation that could further ratchet up US-China tensions and distract from more urgent priorities.

*There actually is scientific evidence against the "escaped from a lab" theory."
He then cites five different scientists who wrote in Nature magazine that "We do not believe that any type of laboratory-based scenario is plausible."

In fact, "Most experts push back on the lab leak theory," CNN reported earlier this month. "I think it has no credibility," they were told by Vincent Racaniello, a microbiology professor at Columbia University who hosts a podcast called "This Week in Virology."

And they got the same response from Dr. Simon Anthony, a professor at the public health grad school of Columbia University and a key member of PREDICT. "It all feels far-fetched. Lab accidents do happen, we know that, but... there's certainly no evidence to support that theory."

That's also the opinion of America's intelligence community. Business Insider writes: The US intelligence community has also been investigating whether the virus was collected by researchers and then accidentally leaked from a Chinese lab but has found no evidence to date backing it up, according to Politico, which cited multiple sources familiar with the matter. Or, as Politico puts it: Congressional intelligence committees have been asking various agencies if hard evidence exists to support it. So far, there is none, multiple sources familiar with the matter told POLITICO.
UPDATE (4/19/20): On Sunday even Dr. Deborah Birx, the White House's Coronavirus Task Force response coordinator, acknowledged "I don't have evidence that it was a laboratory accident."

GeekWire reports: The University of Washington School of Medicine's Virology Lab is reporting encouraging results from trial runs of a new test from Abbott Laboratories that detects the antibodies created by people who have had COVID-19, whether they knew they had it or not. "This is a really fantastic test," Keith Jerome, who leads UW Medicine's virology program, told reporters today. He said UW's lab could process 4,000 samples per day starting next week, and conceivably ramp up to 14,000 samples per day within a couple of weeks.

The test will be made available through health care providers, in medical clinics or perhaps through workplaces... Epidemiologists say knowing who has had the virus will be key to tracking the true spread of COVID-19, and giving assurances to people who are returning to school and work — particularly in front-line jobs ranging from first responders and health care workers to grocery store clerks.

"It's possible this could be part of a back-to-work process," Jerome said. It's not yet clear how much immunity people develop to COVID-19 in the course of fighting off the virus, but if SARS-CoV-2 behaves like other coronaviruses, people with antibodies should have at least some protection from re-infection...

There's also a chance that being able to detect antibodies for COVID-19 will speed the development of vaccines in the months ahead.
1 million of the tests will be shipped this week in the U.S., and up to 4 million in the month of April, GeekWire reports.

And by June the company plans to be shipping 20 million tests per month.

This week the Washington Post asked their "business of health care" reporter to explain the true status in the scientific community of hydroxychloroquine, an already-approved malaria drug also used to control inflammation in lupus and rheumatoid arthritis patients.

"There is no clear evidence that the drugs work against the coronavirus," he writes, "despite their use by hospitals and doctors in the United States and other countries since the outbreak began." Their antiviral properties have been proved in test tubes, but rigorous clinical trials to test their effectiveness in humans have not been completed. Limited studies on coronavirus patients have been published by researchers in France and China, but their extremely small size and other problems prevented them from being statistically significant. The French study included a combination of hydroxychloroquine with the antibiotic azithromycin that showed benefit in six patients... Another study in 11 patients in France showed no evidence the regimen works. A Chinese study also showed no benefit over the standard course of treatment.

Mainstream scientists caution against using the drugs without more evidence they are effective... The dangerous side effects of the drugs are much better known. Most seriously, the drugs can trigger arrhythmia, which can lead to a fatal heart attack in patients with cardiovascular disease or who are taking certain drugs, including anti-depression medications. Doctors recommend screening with an electrocardiogram to prevent the drug from being given to the 1 percent of patients at the greatest risk of a cardiac event. The drugs also can cause vision loss called retinopathy with long-term use, and chloroquine has been associated with psychosis...

As the coronavirus has spread from China across the world and to the United States, the dire reality is that there is no vaccine and no approved drug available to treat the serious respiratory symptoms that are claiming thousand of lives.
Long-time Slashdot reader UnknowingFool shares doubts raised about that small French study, as even its publisher now acknowledges it "does not meet" their own expected standards.

The Post does note that multiple trials are "ongoing" (though six different research centers testing the drug told CNN it would be "months" before results were known). But the Post adds that already "public and political interest has caused runs, hoarding and severe shortages in recent weeks."

The New York Post reports that a COVID-19 vaccine "may be six months away, according to a researcher leading a team of scientists in England." "I think there's a high chance that it will work based on other things that we have done with this type of vaccine," Sarah Gilbert, a professor of virology at Oxford told The Times of London. "It's not just a hunch and as every week goes by we have more data to look at. I would go for 80 percent, that's my personal view."
Gilbert added that if they can find places that haven't imposed a lockdown, "we will get our efficacy results very quickly."

America and Israel have also reported encouraging progress on a vaccine. And in the Netherlands and Australia, researchers are testing the effectiveness of the BCG tuberculosis vaccine developed in the 1920s (with more tests being scheduled for Africa, and experiments in the U.K.) UPI reports researchers in the Netherlands "have started recruiting 1,000 healthcare workers, who are at high risk for COVID-19, in eight hospitals who will receive either the BCG vaccine or a placebo."

The Times of London reports that the U.K. government "signalled that it would be willing to fund the manufacture of millions of doses in advance" if the results of professor Gilbert's research looked promising. "This would allow it to be available immediately to the public if it were proven to work.

"With ministers struggling to find a strategy to exit the lockdown, long-term hopes of a return to normality rely on a vaccine."

"Apple announced Sunday it's launched a companywide effort to design, produce and ship face shields to medical workers battling the coronavirus outbreak," reports CNET: The first shipment was delivered this week to a Kaiser facility in the Santa Clara Valley, Apple CEO Tim Cook said in a video posted to Twitter.

"Teams across Apple have been working hard on ways we can support our heroic front-line medical professionals," Cook said, explaining that the fully adjustable shields pack flat and can be assembled in two minutes. "The feedback from doctors was very positive." "We plan to ship over 1 million by the end of this week, and over 1 million per week after that," he said. Cook said the company is coordinating with health and government officials across the US to get the shields delivered where they're needed and hopes to expand distribution beyond the US quickly.
"Apple is dedicated to supporting the worldwide response to COVID-19," Apple's CEO said on Twitter. "We've now sourced over 20M masks through our supply chain."

Elon Musk shared a new video today from Tesla Engineering. "We're trying to make some ventilators from some car parts, so we can help the medical industry without taking away from their supply," it begins. (All three people who appear in the video are wearing a face mask.)

It ends with a demonstration of a prototype using a touchscreen display from the Model 3 infotainment system. "There's still a lot of work to do," the video concludes, "but we're giving it our best effort to make sure we can help some people out there."

Yesterday ventilator manufacturer Medtronic also tweeted that Musk's other company SpaceX "is now making a vital component for critical care ventilators," meaning more of the devices would arrive sooner for Covid-19 patients.

Meanwhile, the New York Post writes: Musk promised last month to shift production to the sorely-needed medical devices, but evidently found that buying existing ventilators with his own largesse was more practical. He shelled out to send 1,000 of the life-saving machines to California, and also vowed to buy some for New York, earning the gratitude of Mayor Bill de Blasio. Musk made good, with the city's public hospital system on Saturday tweeting their gratitude for ventilators Tesla donated, now in use at Lincoln Hospital in The Bronx.

But, with the apex of the contagion possibly upon New York, Cuomo said Sunday that time had run out for Tesla to make new ventilators. "Their time-frame, frankly, doesn't work for our immediate apex, because whether we're talking two days or 10 days, you're not going to make ventilators at that time," said Cuomo, noting that the hang-up is that some parts have to come from overseas.

"From face-shields to respirator valves, 3-D printer owners pitch in to the efforts to provide PPE to Australian hospitals," writes davecb (Slashdot reader #6,526).

It's not only happening in Australia. But the Guardian talked to Mat Bowtell, a former Toyota engineer in Australia who's using fourteen 3D printers to manufacture thousands of face shields for healthcare workers. And citing 3D printing, the director of a not-for-profit working with the government says the country has an "incredible onshore capability" to respond to the pandemic: "The 3D printing capability onshore is a massive distinguisher for Australia to step up to the crisis," he said. When asked how else 3D printing might be deployed in practice, Goennemann points to the supply of ventilators, which are needed to assist breathing in the most seriously ill Covid-19 patients... Goennemann says Resmed, the main ventilator manufacturer, could struggle to get parts due to the disruption of global supply chains. That's where 3D printing can help. "I don't want to speak on behalf of Resmed, but that's an area where we have critical supply, and parts can be 3D printed onshore rather than being procured offshore," he said...

For Bowtell, the decision to shift his production to face shields had nothing to do with profit. It was about doing what he could in the most extraordinary of times. "It's about survival at the moment," Bowtell said. "Just helping people to get through this together."
Reuters also reported that one Italian company used its 3D printers to manufacture valves for respirators for its local hospital. And a paywalled article at Fortune also describes the team building an open source ventilator, while also noting that more than 4,800 people with 3D printers "have, via a public Google Doc, signed up to help print everything from face shields to ventilator parts for their local hospitals."

They also highlight Budmen Industries, an upstate New York company selling 3D printers that has now also printed 1,492 face shields for New York medical workers. And finally there's the CoVent-19 Challenge, "an open innovation 8-week Grand Challenge for engineers, innovators, designers, and makers" on the GrabCAD Challenges platform, to create "a rapidly deployable, minimum viable mechanical ventilator for patients with COVID-19 related ventilator-dependent lung injury."

"Crowds flock to Santa Clara County test sites to learn if they have antibodies to COVID-19," reports the Bay Area Newsgroup, citing long lines of cars forming at three Stanford research sites for the drive-through tests: The 2,500 test slots on Friday and Saturday filled up within hours, as news of the project -- the first large scale study of its type in the U.S. -- spread quickly through the county. The test detects protective antibodies to the virus rather than the virus itself. This gives scientists a snapshot of how many people in the county have already been infected, but weren't seriously sick and didn't realize it. And it tells residents whether they carry potentially protective antibodies -- so may be immune to future infection. "This is critical information," said principal investigator Dr. Eran Bendavid, an infectious disease specialist and professor of medicine with Stanford Health Policy.

"We will show the country what to do and how to do it," he said... It can guide public health measures and policies -- showing where the epidemic is heading, when it is safe to lift shelter-in-place restrictions and how far away we are from "herd immunity," when it becomes harder for a virus to spread...

This approach, called a "serological test," remains a research tool and is not yet widely available in the United States. Stanford is working on a second test that will be deployed for more widespread use. U.S. Food and Drug Administration approval is imminent -- "within hours, not days," [California governor] Newsom said.... Meanwhile, a global effort to study antibodies is being coordinated by the World Health Organization. Called Solidarity II, more than a half dozen countries will pool their findings from large-scale testing...

It is not yet proven that these antibodies actually provide protection... But there are promising clues that COVID-19 might act like it's closest cousin, the SARS virus, which triggers an immune response that persists for at least three years. In a Chinese study of rhesus monkeys, COVID-19 antibodies protected the animals from a second infection.

If protected, people could potentially return to work. There is also the prospect that the antibodies could be used as therapy against the disease. Dozens of companies are working to develop antibody tests, as are researchers at the Centers for Disease Control and Prevention.
The article notes that United Biomedical Inc will "soon" also provide free antibody testing to all 8,000 residents in Telluride, Colorado, and in some countries in Asia.

Long-time Slashdot reader theodp writes: With the CDC now recommending wearing cloth face coverings in public settings, Etsy has called in the cavalry, encouraging additional sellers on its platform to start creating and offering face masks to help meet an already significant demand for fabric face masks. "We believe that the Etsy community is uniquely positioned to address this crucial need during a global health crisis," Etsy CEO Josh Silverman said in a statement. "We hope that increasing the availability of fabric, non-medical grade face masks from Etsy sellers will allow more medical and surgical masks to reach the people who need them most: front-line health care workers."